Systemic T cell adoptive immunotherapy of malignant gliomas

Journal of Neurosurgery

Volumn 89, Issue 1, 1998, Pages 42-51

  Plautz, Gregory E ^a   Barnett, Gene H ^a   Miller, David W ^a   Cohen, Bruce H ^a   Prayson, Richard A ^a   Krauss, John C ^a   Luciano, Mark ^a   Kangisser, Debra B ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Clinical trial; Malignant glioma; Staphylococcal enterotoxin A; T lymphocyte

Indexed keywords

CORTICOSTEROID;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL TRANSFER; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HUMAN; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031832638     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1998.89.1.0042     Document Type: Article

References (51)

1. Alexander JP, Kudoh S, Melsop KA, et al: T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 53:1380-1387, 1993
2. Arca MJ, Krauss JC, Aruga A, et al: Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 3:39-47, 1996
3. Barba D, Saris SC, Holder C, et al: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175-182, 1989
4. Boiardi A, Silvani A, Ruffini PA, et al: Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39:193-197, 1994
5. Brem H, Piantadosi S, Burger PC, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012, 1995
6. Brooks WH, Caldwell HD, Morata RH: Immune responses in patients with gliomas. Surg Neurol 2:419-423, 1974
7. Brooks WH, Netsky MG, Normansell DE, et al: Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136:1631-1647, 1972
8. Castelli MG, Chiabrando C, Fanelli R, et al: Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49:1505-1508, 1989
9. Chachoua A, Oratz R, Liebes L, et al: Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother 16:132-141, 1994
10. Chang AE, Aruga A, Cameron MJ, et al: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15: 796-807, 1997
11. Chang AE, Yoshizawa H, Sakai K, et al: Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53:1043-1050, 1993
12. Chou T, Chang AE, Shu S: Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. J Immunol 140:2453-2461, 1988
13. Disis ML, Bernhard H, Shiota FM, et al: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88:202-210, 1996
14. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543, 1993
15. Fakhrai H, Dorigo O, Shawler DL, et al: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914, 1996
16. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:5613-5616, 1993
17. Goedegebuure PS, Douville LM, Li H, et al: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13: 1939-1949, 1995
18. Hayes RL, Koslow M, Hiesiger EM, et al: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840-852, 1995
19. Head JR, Griffin WST: Functional capacity of solid tissue implants in the brain: evidence for immunological privilege. Proc R Soc B 224:375-387, 1985
20. Huettner C, Paulus W, Roggendorf W: Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146:317-322, 1995
21. Inge TH, Hoover SK, Susskind BM, et al: Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor ß1. Cancer Res 52:1386-1392, 1992
22. Inoue M, Plautz GE, Shu S: Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res 56:4702-4708, 1996
23. Jacobs SK, Wilson DJ, Kornblith PL, et al: Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 64:743-749, 1986
24. Jager E, Ringhoffer M, Dienes HP, et al: Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54-62, 1996
25. Kruse CA, Schiltz PM, Bellgrau D, et al: Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neurooncol 19:161-168, 1994
26. Kwak LW, Young HA, Pennington RW, et al: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93:10972-10977, 1996
27. Lillehei KO, Mitchell DH, Johnson SD, et al: Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28: 16-22, 1991
28. Mahaley MS Jr, Brooks WH, Roszman TL, et al: Immuno-biology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 46:467-476, 1977
29. Matsumura T, Sussman JJ, Krinock RA, et al: Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes. Cancer Res 54:2744-2750, 1994
30. Maxwell M, Galanopoulos T, Neville-Golden J, et al: Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76:799-804, 1992
31. Medawar PW: Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58-69, 1948
32. Merchant RE, Merchant LH, Cook SHS, et al: Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23:725-732, 1988
33. Peng L, Shu S, Krauss JC: Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol 178:24-32, 1997
34. Plautz GE, Inoue M, Shu S: Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors. Cell Immunol 171:277-284, 1996
35. Plautz GE, Touhalisky JE, Shu S: Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 178:101-107, 1997
36. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1675-1680, 1988
37. Roszman TL, Brooks WH: Immunobiology of primary intracranial tumors. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumors. Clin Exp Immunol 39:395-402, 1980
38. Saris SC, Patronas NJ, Rosenberg SA, et al: The effect of intravenous interleukin-2 on brain water content. J Neurosurg 71: 169-174, 1989
39. Saris SC, Rosenberg SA, Friedman RB: Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 69:29-34, 1988
40. Sawamura Y, Hosokawa M, Kuppner MC, et al: Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 49:1843-1849, 1989
41. Shu S, Chou T, Rosenberg SA: Generation from tumor-bearing mice of lymphocytes with in vitro therapeutic efficacy. J Immunol 139:295-304, 1987
42. Shu S, Krinock RA, Matsumura T, et al: Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 152:1277-1288, 1994
43. Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537-1546, 1997
44. Sussman JJ, Shu S, Sondak VK, et al: Activation of T lymphocytes for the adoptive immunotherapy of cancer. Ann Surg Oncol 1:296-306, 1994
45. Sussman JJ, Wahl WL, Chang AE, et al: Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors. J Immunother 18:35-44, 1995
46. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758, 1993
47. Wahl WL, Sussman JJ, Shu S, et al: Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. J Immunother 15:242-250, 1994
48. Walker MD, Alexander E Jr, Hunt WE: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative trial. J Neurosurg 49:333-343, 1978
49. Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 303:1323-1329, 1980
50. Yoshida S, Tanaka R, Takai N, et al: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 48:5011-5016, 1988
51. Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147: 729-737, 1991